

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM384329

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ANI PHARMACEUTICALS, INC.		05/12/2016	Corporation: DELAWARE
ANIP ACQUISITION COMPANY		05/12/2016	Corporation: DELAWARE
ANIP PARTNER,LLC		05/12/2016	Limited Liability Company: DELAWARE
AP EUROPEAN HOLDINGS, LLC		05/12/2016	Limited Liability Company: DELAWARE
ANIP CO-OP, LLC		05/12/2016	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	CITIZENS BUSINESS CAPITAL, A DIVISION OF CITIZENS ASSET FINANCE, INC., AS AGENT		
Street Address:	28 STATE STREET		
City:	BOSTON		
State/Country:	MASSACHUSETTS		
Postal Code:	02109		
Entity Type:	Corporation: NEW YORK		
PROPERTY NUMBERS Total: 9			
Property Type	Number	Word Mark	
Registration Number:	2585471	BIOSANTE	
Registration Number:	3058248	LIBIGEL	
Registration Number:	1147470	LITHOBID	
Registration Number:	683928	VANCOCIN	
Registration Number:	808375	CORTENEMA	
Registration Number:	1154480	REGLAN	
Registration Number:	788963	INDERAL	
Registration Number:	1900307	INDERAL	
Registration Number:	1255059		
CORRESPONDENCE DATA			

OP \$240.00 2585471

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 877-374-6188
Email: ipteam@nationalcorp.com
Correspondent Name: Patricia Martinez
Address Line 1: 600 Wilshire Boulevard, Suite 980
Address Line 2: National Corporate Research, LTD
Address Line 4: Los Angeles, CALIFORNIA 90017

NAME OF SUBMITTER:	ANDREW NASH
---------------------------	-------------

SIGNATURE:	/ANDREW NASH/
-------------------	---------------

DATE SIGNED:	05/13/2016
---------------------	------------

Total Attachments: 17

source=FINAL -- Intellectual Property Security Agreement -- ANI#page1.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page2.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page3.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page4.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page5.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page6.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page7.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page8.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page9.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page10.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page11.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page12.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page13.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page14.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page15.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page16.tif
source=FINAL -- Intellectual Property Security Agreement -- ANI#page17.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Agreement”), dated as of May 12, 2016, by and among (a) **ANI PHARMACEUTICALS, INC.**, a Delaware corporation (the “Borrower Representative”), (b) each of the Persons listed on Schedule I hereto (each such Person, together with the Borrower Representative, individually, a “Borrower” and, collectively, the “Borrowers”), (c) each of the Persons listed on Schedule II hereto (each such Person, individually, a “Guarantor” and, collectively, the “Guarantors”) (the Borrowers and the Guarantors are hereinafter referred to, individually, as a “Grantor” and, collectively with any other Person now or hereafter party hereto, as the “Grantors”), and (d) **CITIZENS BUSINESS CAPITAL**, a division of Citizens Asset Finance, Inc., as agent (in such capacity, the “Agent”) for its own benefit and the benefit of the other Lenders (as defined in the Loan Agreement referred to below), in consideration of the mutual covenants contained herein and benefits to be derived herefrom.

WITNESSETH:

WHEREAS, reference is made to that certain Loan and Security Agreement, dated as of the date hereof (as amended, restated, supplemented or otherwise modified and in effect from time to time, the “Loan Agreement”), by, among others, (i) the Grantors, (ii) the Lenders from time to time party thereto (each, individually, a “Lender” and, collectively, the “Lenders”), (iii) the Agent, and (iv) Citizens Bank, N.A., as Issuing Bank, pursuant to which the Lenders have agreed to make Loans to the Borrowers, and the Issuing Bank has agreed to issue Letters of Credit for the account of the Borrowers, upon the terms and subject to the conditions specified in the Loan Agreement; and

WHEREAS, pursuant to the Loan Agreement, each of the Grantors, among others, has granted to the Agent (for its own benefit and the benefit of the other Lenders) a security interest in and to the Collateral (as defined in the Loan Agreement), as security for the Obligations; and

WHEREAS, the obligations of the Lenders to make Loans and of the Issuing Bank to issue Letters of Credit are each conditioned upon, among other things, the execution and delivery by the Grantors of an agreement in the form hereof, pursuant to which each Grantor confirms its grant of security interest provided in the Loan Agreement and further grants to the Agent (for its own benefit and the benefit of the other Lenders) a security interest in and to the IP Collateral (as defined herein).

NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in this Agreement, and for good and valuable consideration, the receipt of which is hereby acknowledged, the Grantors and the Agent, on its own behalf and on behalf of the other Lenders (and each of their respective successors or assigns), hereby agree as follows:

SECTION 1. Definitions.

1.1 Generally. All references herein to the UCC shall mean the Uniform Commercial Code as in effect from time to time in the State of New York; provided, however, that if a term is defined in Article 9 of the UCC differently than in another Article thereof, the term shall have the meaning set forth in Article 9; provided further that, if by reason of mandatory provisions of

law, perfection, or the effect of perfection or non-perfection, of the security interest in any IP Collateral or the availability of any remedy hereunder is governed by the Uniform Commercial Code as in effect in a jurisdiction other than New York, "UCC" means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such perfection or effect of perfection or non-perfection or availability of such remedy, as the case may be.

1.2 Definition of Certain Terms Used Herein. Unless the context otherwise requires, all capitalized terms used but not defined herein shall have the meanings set forth in the Loan Agreement. In addition, as used herein, the following terms shall have the following meanings:

"Agent" shall have the meaning assigned to such term in the preamble of this Agreement.

"Borrower Representative" shall have the meaning assigned to such term in the preamble of this Agreement.

"Borrowers" shall have the meaning assigned to such term in the preliminary statement of this Agreement.

"Copyrights" shall mean all copyrights and like protections in each work of authorship or derivative work thereof owned by any Grantor, whether registered or unregistered and whether published or unpublished, including, without limitation, the United States copyright registrations and copyright applications listed on **EXHIBIT A** annexed hereto and made a part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

"Copyright Office" shall mean the United States Copyright Office or any other federal governmental agency of the United States which may hereafter perform its functions.

"Grantor" and "Grantors" shall have the meaning assigned to such terms in the preamble of this Agreement.

"Guarantor" shall have the meaning assigned to such term in the preamble of this Agreement.

"Guarantors" shall have the meaning assigned to such term in the preliminary statement of this Agreement.

"Intellectual Property" shall have the meaning assigned to such term in SECTION 3 of this Agreement.

"IP Collateral" shall have the meaning assigned to such term in SECTION 2 of this Agreement.

"Loan Agreement" shall have the meaning assigned to such term in the preliminary statement of this Agreement.

“Patents” shall mean all patents and applications for patents owned by any Grantor, and the inventions and improvements therein disclosed, and any and all divisions, revisions, reissues and continuations, continuations-in-part, extensions, and reexaminations of said patents including, without limitation, the United States patent registrations and patent applications listed on **EXHIBIT B** annexed hereto and made a part hereof.

“PTO” shall mean the United States Patent and Trademark Office or any other federal governmental agency of the United States which may hereafter perform its functions.

“Trademarks” shall mean all trademarks, trade names, corporate names, company names, domain names, business names, fictitious business names, trade dress, trade styles, service marks, designs, logos and other source or business identifiers owned by any Grantor, whether registered or unregistered, including, without limitation, the United States trademark registrations and trademark applications listed on **EXHIBIT C** annexed hereto and made a part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

1.3 Rules of Interpretation. The rules of interpretation specified in Sections 1.2 and 1.3 of the Loan Agreement shall be applicable to this Agreement.

SECTION 2. Grant of Security Interest. In furtherance and as confirmation of the security interest granted by the Grantors to the Agent (for the benefit of the Lenders) under the Loan Agreement, and as further security for the prompt payment or performance, as the case may be, of all Obligations, each of the Grantors hereby ratifies such security interest and grants to the Agent (for its own benefit and the benefit of the other Lenders) a continuing security interest in and Lien upon all of the present and future right, title and interest of such Grantor in and to the following property, and each item thereof, whether now owned or existing or hereafter acquired or arising, together with all products, proceeds, substitutions, and accessions of or to any of the following property (collectively, the “IP Collateral”):

(a) All Copyrights;

(b) All Patents;

(c) All Trademarks;

(d) All renewals of any of the foregoing;

(e) All trade secrets, know-how and other proprietary information; works of authorship and other copyright works (including copyrights for computer programs), and all tangible and intangible property embodying the foregoing; inventions (whether or not patentable) and all improvements thereto; industrial design applications and registered industrial designs; books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases, and other physical manifestations, embodiments or incorporations of any of the foregoing, and all other Intellectual Property and proprietary rights of any of the Grantors;

(f) All General Intangibles connected with the use of, or related to, any and all Intellectual Property (including, without limitation, all goodwill of each Grantor and its business, products and services appurtenant to, associated with, or symbolized by, any and all Intellectual Property and the use thereof);

(g) All income, royalties, damages and payments now and hereafter due and/or payable under and with respect to any of the foregoing, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements, misappropriations or dilutions thereof;

(h) The right to sue for past, present and future infringements, misappropriations, and dilutions of any of the foregoing; and

(i) All of the Grantors' rights corresponding to any of the foregoing throughout the world.

Notwithstanding anything contained herein to the contrary, in no event shall the security interest granted under this SECTION 2 include any Excluded Property.

SECTION 3. Protection of Intellectual Property By Grantors. Except as set forth below in this SECTION 3, each of the Grantors shall undertake the following with respect to each of the items respectively described in Sections 2(a), (b), (c), (d), (e) and (f) (collectively, the "Intellectual Property"):

(a) Pay all renewal fees and other fees and costs associated with maintaining the Intellectual Property and with the processing and prosecution of the Intellectual Property and take all other steps reasonably necessary to maintain each registration of the Intellectual Property, except, in each case, to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect.

(b) Take all actions reasonably necessary to prevent any of the Intellectual Property from becoming forfeited, abandoned, dedicated to the public, invalidated or impaired in any way, except, in each case, to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect.

(c) At the Grantors' sole cost, expense, and risk, pursue the processing and prosecution of each application for registration which is the subject of the security interest created herein and not abandon or delay any such efforts, except, in each case, to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect.

(d) At the Grantors' sole cost, expense, and risk, take any and all action which the Grantors reasonably deem necessary or desirable under the circumstances to protect the Intellectual Property from infringement, misappropriation or dilution, including, without limitation, the prosecution and defense of infringement actions, except, in each case, to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect.

SECTION 4. Grantors' Representations and Warranties. In addition to any representations and warranties contained in any of the other Loan Documents, each Grantor represents and warrants that:

(a) **EXHIBIT A** is a true, correct and complete list of all United States Copyrights owned by such Grantor as of the date hereof.

(b) **EXHIBIT B** is a true, correct and complete list of all United States Patents owned by such Grantor as of the date hereof.

(c) **EXHIBIT C** is a true, correct and complete list of all United States Trademarks owned by such Grantor as of the date hereof.

(d) All IP Collateral owned by such Grantor is, and shall remain, free and clear of all Liens, encumbrances, or security interests in favor of any Person, other than Permitted Liens.

(e) Such Grantor owns, or is licensed to use, all Intellectual Property reasonably necessary for the conduct of its business as currently conducted. To the knowledge such of Grantor, no claim has been asserted and is pending by any Person challenging or questioning the use by such Grantor of any of its Intellectual Property, or the validity or effectiveness of any of its Intellectual Property, that could reasonably be expected to have a Material Adverse Effect. Such Grantor considers that the use by such Grantor of the Intellectual Property does not infringe the rights of any Person in any material respect. To the knowledge of such Grantor, no holding, decision or judgment has been rendered by any Governmental Authority which would limit, cancel or question the validity of, or such Grantor's rights in, any Intellectual Property in any respect that could reasonably be expected to have a Material Adverse Effect.

(f) Such Grantor shall give the Agent prompt written notice, with reasonable detail, following the occurrence of any of the following:

(i) Such Grantor's obtaining rights to, and filing applications for registration of, any new Intellectual Property, or otherwise acquiring ownership of any registered Intellectual Property (other than the acquisition by such Grantor of the right to sell products containing the trademarks of others in the ordinary course of such Grantor's business).

(ii) Such Grantor's becoming entitled to the benefit of any registered Intellectual Property whether as licensee or licensor (other than commercially available off the shelf computer programs, products or applications and such Grantor's right to sell products containing the trademarks of others in the ordinary course of such Grantor's business).

(iii) Such Grantor's actual knowledge, that any application or registration relating to any Intellectual Property may, other than as provided in SECTION 3 above, become forfeited, abandoned or dedicated to the public, or of any adverse determination or development (including, without limitation, the

institution of, or any such determination or development in, any proceeding in the PTO, the Copyright Office or any court or tribunal) regarding such Grantor's ownership of, or the validity or enforceability of, any Intellectual Property or such Grantor's right to register the same or to own and maintain the same.

SECTION 5. Agreement Applies to Future Intellectual Property.

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in subsections (i) and (ii) of SECTION 4(f), above, all of which shall be deemed to be and treated as "Intellectual Property" within the meaning of this Agreement. Upon the acquisition by any Grantor of any additional Intellectual Property, such Grantor shall promptly deliver to the Agent an updated **EXHIBIT A, B, and/or C** (as applicable) to this Agreement and hereby authorizes the Agent to file, at such Grantor's expense, such updated Exhibit as set forth in SECTION 5(b).

(b) Each of the Grantors shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Agent may reasonably request to evidence the Agent's security interest in any Intellectual Property (including, without limitation, filings with the PTO, the Copyright Office or any similar office), and each of the Grantors hereby constitutes the Agent as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all such acts of such attorney being hereby ratified and confirmed; provided, however, that the Agent's taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

SECTION 6. Grantors' Rights To Enforce Intellectual Property. Prior to the occurrence of an Event of Default, the Grantors shall have the exclusive right to sue for past, present and future infringement of the Intellectual Property, including the right to seek injunctions and/or money damages in an effort by the Grantors to protect the Intellectual Property against encroachment by third parties, provided, however, that:

(a) The Grantors provide the Agent with written notice of any Grantor's institution of any legal proceedings to enforce its rights in any Intellectual Property, the infringement of which could reasonably be expected to have a Material Adverse Effect.

(b) Any money damages awarded or received by the Grantors on account of such suit (or the threat of such suit) shall constitute IP Collateral.

(c) Upon the occurrence and during the continuance of any Event of Default, the Agent, by advance written notice to the Grantors, may terminate or limit the Grantors' rights under this SECTION 6.

SECTION 7. Agent's Actions To Protect Intellectual Property. In the event of

(a) any Grantor's failure to observe or perform any of such Grantor's covenants, agreements or other obligations hereunder and such failure continues for ten (10) days after the earlier of such Grantor's knowledge of a breach of any such covenant,

agreement or other obligation or such Grantor's receipt of notice from the Agent of any such breach; and/or

(b) the occurrence and continuance of any other Event of Default,

the Agent, acting in its own name or in that of any Grantor, may (but shall not be required to) act in any Grantor's place and stead and/or in the Agent's own right in connection therewith.

SECTION 8. Rights Upon Default. Upon the occurrence and during the continuance of an Event of Default, in addition to all other rights and remedies, the Agent may exercise all rights and remedies of a secured party under the UCC, with respect to the Intellectual Property, in addition to which the Agent may sell, license, assign, transfer, or otherwise dispose of the Intellectual Property, subject to those restrictions to which such Grantor is subject under Applicable Law and by contract.

SECTION 9. Agent As Attorney-In-Fact.

(a) Each of the Grantors hereby irrevocably makes, constitutes and appoints the Agent (and all officers, employees or agents designated by the Agent) as and for such Grantor's true and lawful agent and attorney-in-fact, and in such capacity the Agent shall have the right, with power of substitution for each Grantor and in each Grantor's name or otherwise, for the use and benefit of the Agent and the other Lenders:

(i) To supplement and amend from time to time **EXHIBITS A, B and C** of this Agreement to include any newly developed, applied for, registered, or acquired Intellectual Property of such Grantor and any intent-to-use Trademark applications for which a statement of use or an amendment to allege use has been filed and accepted by the PTO.

(ii) Following the occurrence and during the continuance of any Event of Default, to exercise any of the rights and powers referenced herein.

(iii) Following the occurrence and during the continuance of any Event of Default, to execute all such instruments, documents, and papers as the Agent reasonably determines to be necessary or desirable in connection with the exercise of such rights and remedies and to cause the sale, license, assignment, transfer, or other disposition of the Intellectual Property, subject to those restrictions to which such Grantor is subject under Applicable Law and by contract.

(b) The power of attorney granted herein, being coupled with an interest, shall be irrevocable until this Agreement is terminated in writing by a duly authorized officer of the Agent.

(c) The Agent shall not be obligated to do any of the acts or to exercise any of the powers authorized by SECTION 9(a), but if the Agent elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to any Grantor for any

act or omission to act, except where a court of competent jurisdiction determines by final and nonappealable judgment that the subject act or omission to act has resulted from the gross negligence or willful misconduct of the Agent.

SECTION 10. Agent's Rights. Any use by the Agent of the Intellectual Property, as authorized hereunder in connection with the exercise of the Agent's rights and remedies under this Agreement and the Loan Agreement shall be coextensive with the Grantors' rights thereunder and with respect thereto and without any liability for royalties or other related charges.

SECTION 11. Intent. This Agreement is being executed and delivered by the Grantors for the purpose of registering and confirming the grant of the security interest of the Agent in the IP Collateral with the PTO and the Copyright Office. It is intended that the security interest granted pursuant to this Agreement is granted as a supplement to, and not in limitation of, the security interest granted to the Agent, for its own benefit and the benefit of the other Lenders, under the Loan Agreement. All provisions of the Loan Agreement (including, without limitation, the rights, remedies, powers, privileges and discretions of the Agent thereunder) shall apply to the IP Collateral. In the event of a conflict between this Agreement and the Loan Agreement, the terms of this Agreement shall control with respect to the IP Collateral and the terms of the Loan Agreement shall control with respect to all other Collateral.

SECTION 12. Further Assurances. Each Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further documents, financing statements, agreements and instruments and take all such further actions as the Agent may from time to time reasonably request to better assure, preserve, protect and perfect the security interest in the IP Collateral granted pursuant to this Agreement and the rights and remedies created hereby or the validity or priority of such security interest, including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the security interest and the filing of any financing statements or other documents in connection herewith or therewith.

SECTION 13. Termination; Release of IP Collateral. Except for those provisions which expressly survive the termination thereof, this Agreement and the security interest granted herein shall terminate upon payment in full of the Obligations in accordance with Section 5.2.3 of the Loan Agreement, at which time the Agent shall execute and deliver to the Grantors, at the Grantors' expense, all UCC termination statements, releases and similar documents that the Grantors shall reasonably request to evidence such termination, in each case in form and substance reasonably satisfactory to the Agent; provided, however, that the Loan Agreement, this Agreement, and the security interest granted herein shall be reinstated if at any time payment, or any part thereof, of any Obligation is rescinded or must otherwise be restored by any Lender upon the bankruptcy or reorganization of any Grantor. Any execution and delivery of termination statements, releases or other documents pursuant to this SECTION 13 shall be without recourse to, or warranty by, the Agent or any other Lender.

SECTION 14. Choice of Laws. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW


YORK WITHOUT GIVING EFFECT TO ANY APPLICABLE LAW THAT WOULD CAUSE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, the Grantors and the Agent have caused this Agreement to be executed by their duly authorized officers as of the date first above written.

GRANTORS:

ANI PHARMACEUTICALS, INC.


By: 
Name: Arthur S. Przybyl
Title: President and Chief Executive Officer

ANIP ACQUISITION COMPANY

By: 
Name: Arthur S. Przybyl
Title: President and Chief Executive Officer


ANIP PARTNER, LLC

By: ANI Pharmaceuticals, Inc., its sole member

By: 
Name: Arthur S. Przybyl
Title: President and Chief Executive Officer

AP EUROPEAN HOLDINGS, LLC

By: ANI Pharmaceuticals, Inc., its sole member


By: 
Name: Arthur S. Przybyl
Title: President and Chief Executive Officer

ANIP CO-OP, LLC

By: ANI Pharmaceuticals C.V., its sole member

By: ANI Partner, LLC, its general partner

By: ANI Pharmaceuticals, Inc., its sole member

By:  _____

Name: Arthur S. Przybyl

Title: President and Chief Executive Officer

AGENT:

CITIZENS BUSINESS CAPITAL, a division of
Citizens Asset Finance, Inc.

By: 

Name: _____

Title: _____

Kevin M. White
Vice President

Signature Page to Intellectual Property Security Agreement

TRADEMARK
REEL: 005792 FRAME: 0366

SCHEDULE I

Borrowers other than the Borrower Representative

ANIP Acquisition Company

Schedule I to Intellectual Property Security Agreement

SCHEDULE II

Guarantors

ANIP Partner, LLC

AP European Holdings, LLC

ANIP Co-op, LLC

Schedule II to Pledge Agreement

EXHIBIT A

List of Copyrights

None

Exhibit A to Intellectual Property Security Agreement

EXHIBIT B

List of Patents

Chain of Title	Assignment Reel/Frame	Title	Status	Application No.	Application Date	Publication No.	Publication Date
Inventors assigned Application to Biosante Pharmaceuticals who merged with ANI Pharmaceuticals, Inc. (DE Corp.)	027149/0878 031790/0880	COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS	Published - Non-Final Office Action mailed on Feb-22-2016	13/212,051	Aug-17-2011	2012-0046264	Feb-23-2012
Inventors assigned Application to Biosante Pharmaceuticals who merged with ANI Pharmaceuticals, Inc. (DE Corp.)	026839/0972 031791/0239	METHODS FOR DECREASING CARDIOVASCULAR RISK IN POSTMENOPAUSAL WOMEN	Published - Non-Final Office Action mailed on Apr-8-2016	13/135,999	Jul-20-2011	2012-0022033	Jan-26-2012
Inventors assigned Application to Biosante Pharmaceuticals who merged with ANI Pharmaceuticals, Inc. (DE Corp.)	026739/0666 031790/0681	METHODS FOR TREATING SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK	Final Office Action mailed Apr-17-2016	13/135,224	Jun-29-2011	2012-0004204	1-5-2012

Exhibit B to Intellectual Property Security Agreement

EXHIBIT C

List of Trademarks


<u>Owner</u>	<u>Title</u>	<u>Image</u>	<u>Status</u>	<u>Application No.</u>	<u>Application Date</u>	<u>Registration No.</u>	<u>Registration Date</u>
ANI Pharmaceuticals, Inc. (DE Corp.)	BIOSANTE		Registered	78/058343		2585471	Jun-25-2002
ANI Pharmaceuticals, Inc. (DE Corp.)	LIBIGEL		No Action - Registered	78/420072	May-17-2004	3058248	Feb-07-2006
ANI Pharmaceuticals, Inc. (DE Corp.)	LITHOBID		Registered	73/219510	Jun-13-1979	1147470	Feb-24-1981
ANI Pharmaceuticals, Inc. (DE Corp.)	VANCOGIN		Registered	72/064010	Dec-10-1958	683928	Aug-25-1959
ANIP Aquisition Company (DE Corp)	CORTENEMA		Registered	72/226791	Aug-30-1965	808375	May-17-1966
ANIP Aquisition Company (DE Corp)	REGLAN		Registered	73/231083	Sep-12-1979	1154480	May-19-1981
ANI Pharmaceuticals, Inc. (DE Corp.)	INDERAL		Registered	72189475	Mar-24-1964	788963	May-04-1965
ANI Pharmaceuticals, Inc. (DE Corp.)	INDERAL		Registered	74534024	Jun-06-1994	1900307	Jun-20-1995
ANI Pharmaceuticals, Inc. (DE Corp.)	Misc. Design		Registered	73305742	Apr-13-1981	1255059	Oct-25-1983

Exhibit C to Intellectual Property Security Agreement